HopeStage
Back to all studies
RecruitingNCT05184335

Brilaroxazine or placebo for schizophrenia: short- and long-term study

About this titleRead the official source — NCT05184335

This study evaluates the safety and effectiveness of Brilaroxazine for people with schizophrenia.

Medication studyAges 18–65United States
The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of Brilaroxazine for people with schizophrenia.

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
Phoenix and 17 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 24, 2022
Recruitment status
Recruiting
Enrollment listed in the registry
690
Sponsor
Reviva Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05184335
Official title
Show the full official title

Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension

Recruitment & locations

Currently recruiting

Phoenix · Bentonville · Little Rock

14 more locations
  • Rogers
  • Garden Grove
  • Lemon Grove
  • Riverside
  • Hollywood
  • Miami Lakes
  • Atlanta
  • Decatur
  • Chicago
  • Gaithersburg
  • Boston
  • Oklahoma City
  • Austin
  • Richardson

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of Brilaroxazine for people with schizophrenia.

Who is behind this study?

The study sponsor is Reviva Pharmaceuticals.

Does this study involve medication?

Yes. The study involves medication, including Brilaroxazine.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies